Items Tagged ‘Gastric Cancer’

December 8th, 2016

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?

By

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be […]

View full entry

Tags: adenocarcinoma, American Society for Clinical Pathology, and American Society of Clinical Oncology, asco, ASCP, CAP, College of American Pathologists, Esophageal Cancer, for human epidermal growth factor receptor 2, Gastric Cancer, Gastroesophageal cancer, HER2 testing


June 28th, 2016

Novel Antibody Improves Survival in Advanced Stomach Cancer

By

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Stomach cancer, […]

View full entry

Tags: 2016, advanced, asco, Gastric Cancer, GEJ cancer, IMAB362, News, Stages III-IV Gastric Cancer, stomach cancer


June 6th, 2016

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

By

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced gastric cancers. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 […]

View full entry

Tags: 2016, antibody, asco, capecitabine, claudin, Ellence, eloxatin, epirubicin, Gastric Cancer, gastric tumors, IMAB362, longer remission


February 18th, 2016

February: Gallbladder and Bile Duct Awareness Month

By

Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released from the liver directly into ducts that carry it to the small intestine, or is stored in the gallbladder and released later. When […]

View full entry

Tags: awareness, bile duct cancer, February, gallbladder cancer, Gastric Cancer, infographic, Liver Cancer, News


February 11th, 2016

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

By

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe […]

View full entry

Tags: Anal Cancer, Breast Cancer, capecitabine, Colon Cancer, fda, fluorouracil, Gastric Cancer, Gastrointestinal Stromal Tumors, life-threatening, Liver Cancer, News, Pancreatic Cancer


February 8th, 2016

Gastric Cancer Risk Factors You Need to Know

By

Successful treatment for stomach or gastric cancer starts with early detection. Most cases of stomach cancer are diagnosed in the advanced stages as there is no routine test for early detection. This makes it very important for people to know their risk for developing stomach cancer. The main risk factors for gastric cancer include: Gender: […]

View full entry

Tags: endoscopy screening, Gastric Cancer, News, risk factors, Screening/Prevention Gastric Cancer, stomach cancer, symptoms


January 4th, 2016

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy

By

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing chemotherapy. Certain types of chemotherapy are strongly associated with causing hair loss, whereupon hair […]

View full entry

Tags: alopecia, Breast Cancer, digitana Dignicap Cooling System, fda, Gastric Cancer, hair loss, News, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


September 9th, 2015

Lynparza Improves Overall Survival in High-Risk Gastric Cancer

By

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 Americans will be diagnosed with gastric […]

View full entry

Tags: ATM, Gastric Cancer, lynparza, metastatic, News, olaparib, paclitaxel, PARP inhibitor, Stages III-IV Gastric Cancer


August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


May 14th, 2015

Reolysin® Receives FDA Designation for Gastric Cancer

By

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc. recently announced the designation in a press release. The FDA grants ODDs in order to advance the evaluation and development of products that demonstrate promise for […]

View full entry

Tags: cancer killing virus, Gastric Cancer, injectable, News, Reolysin, reovirus, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


February 20th, 2015

U.S. FDA Issues Warning about Certain Type of Endoscope

By

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult to clean effectively and may spread dangerous bacteria among patients. An endoscope is thin, tube-like instrument that’s used to look […]

View full entry

Tags: cancer screening, endoscope, fda, fda warning, Gastric Cancer, News, Recurrent Gastric Cancer, Screening/Prevention Gastric Cancer, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


February 12th, 2015

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers

By

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase. These inhibitors may have therapeutic application in the treatment of various types of […]

View full entry

Tags: AMG 337, Esophageal Cancer, esophagus, Gastric Cancer, gastroesophageal junction, Gastrointestinal Cancer, GI tumors, MET inhibitor, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


August 18th, 2014

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates

By

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies have suggested that aspirin can reduce the risk of colon, and other cancer’s of the gastrointestinal tract. (2,3,4) In order to study this […]

View full entry

Tags: aspirin, cancer prevention, Colon Cancer, Esophageal Cancer, Gastric Cancer, News, Screening/Prevention Colon Cancer, Screening/Prevention Esophageal Cancer, Screening/Prevention Gastric Cancer


June 26th, 2014

Apatinib Prolongs Survival in Advanced Gastric Cancer

By

Apatinib significantly improved overall survival according to the results of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is the second leading cause of […]

View full entry

Tags: apatinib, Gastric Cancer, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer